FDA Eyes Adverse Events For Mylan's Wixela Inhub
Assessing Need For Additional Reminders About Differences To Advair
As patients log device complaints for Mylan’s Advair Diskus generic Wixela Inhub, the agency is assessing whether additional reminders about the products’ differences are needed.
You may also be interested in...
Reports of bent needles and injector failures also raise questions about the FDA’s complex product approval process.
Generics sponsors want FDA input before making decisions on pharmacovigilance problems, potentially adding another topic to user fee discussions.
US Energy and Commerce Committee leaders request data on complex generic approvals, guidances, saying additional changes may be needed for faster approvals.